Edition:
India

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

189.28USD
19 Jan 2018
Change (% chg)

-- (--)
Prev Close
$189.28
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,068,124
52-wk High
$191.08
52-wk Low
$150.40

Select another date:

Fri, Jan 19 2018

BRIEF-European Commission Approves Amgen, Allergan's Mvasi

* EUROPEAN COMMISSION APPROVES AMGEN AND ALLERGAN'S MVASI® (BIOSIMILAR BEVACIZUMAB) FOR THE TREATMENT OF CERTAIN TYPES OF CANCER

BRIEF-FDA Approves Addition Of Overall Survival Data To Kyprolis Label

* FDA APPROVES ADDITION OF OVERALL SURVIVAL DATA TO KYPROLIS® (CARFILZOMIB) LABEL

BRIEF-Biocartis And Amgen Sign New Agreement

* REG-BIOCARTIS GROUP NV: BIOCARTIS AND AMGEN SIGN NEW COMPANION DIAGNOSTIC AGREEMENT FOR NOVEL ONCOLOGY COMPOUND

FDA expands use of Amgen's blockbuster drug

Amgen Inc said on Friday that the U.S. Food and Drug Administration approved its drug, Xgeva, to prevent fractures in patients with multiple myeloma.

FDA expands use of Amgen's blockbuster drug

Jan 5 Amgen Inc said on Friday that the U.S. Food and Drug Administration approved its drug, Xgeva, to prevent fractures in patients with multiple myeloma.

BRIEF-FDA Approves XGEVA (Denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma

* FDA APPROVES XGEVA® (DENOSUMAB) FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA

Amgen estimates its U.S. tax bill at over $6 billion as it repatriates cash

NEW YORK, Dec 22 Amgen Inc said it expects to incur tax expenses of $6 billion to $6.5 billion over time as it repatriates cash it has accumulated around the world because of the new U.S. tax law signed by President Donald Trump on Friday.

Amgen's Kyprolis improves overall survival in blood cancer patients

Amgen Inc said on Monday a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer.

UPDATE 1-Amgen's Kyprolis improves overall survival in blood cancer patients

Dec 11 Amgen Inc said on Monday a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer.

Amgen's Kyprolis improves overall survival in blood cancer patients

Dec 11 Amgen Inc said on Monday new data from a late-stage trial testing Kyprolis in combination with two other drugs showed improved overall survival rate in patients with blood cancer.

Select another date: